|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...2627282930313233343536...4041» |
- ||||| glatiramer acetate / Generic mfg.
Enrollment closed: Efficacy and Safety of GTR in Comparison to Copaxone® (clinicaltrials.gov) - May 23, 2013
P3, N=750, Active, not recruiting, Sponsor: Synthon BV
Recruiting --> Active, not recruiting
- ||| Avonex (recombinant IFN-?-1a) / Biogen
New P1 trial: Avonex (clinicaltrials.gov) - May 23, 2013
P1, N=77, Completed, Sponsor: Trio Medicines Ltd.
- Trial completion: Safety of Polyphenon E in Multiple Sclerosis Pilot Study (clinicaltrials.gov) - May 20, 2013
P1, N=10, Completed, Sponsor: Louisiana State University Health Sciences Center in New Orleans
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed: REFINE: Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (clinicaltrials.gov) - May 14, 2013
P2, N=291, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion, Monotherapy: SELECT: Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - May 14, 2013
P2, N=621, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Occupational Therapy in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 13, 2013
P=N/A, N=40, Completed, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Recruiting --> Completed
- sirolimus / Generic mfg.
New P1 trial: Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream (clinicaltrials.gov) - May 13, 2013
P1, N=15, Recruiting, Sponsor: Le Bonheur Children's Hospital
- ||||| Enrollment change: Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease (clinicaltrials.gov) - May 12, 2013
P3, N=1734, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed N=1000 --> 1734
- | Cosentyx (secukinumab) / Novartis
Enrollment change: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - May 8, 2013
P2, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
N=1000 --> 1734 N=63 --> 40
- mexiletine / Generic mfg.
Enrollment open: Mexiletine for the Treatment of Muscle Cramps in ALS (clinicaltrials.gov) - May 8, 2013
P4, N=30, Recruiting, Sponsor: Bjorn Oskarsson, MD
N=63 --> 40 Not yet recruiting --> Recruiting
- ||||| New P2 trial: Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis (clinicaltrials.gov) - May 5, 2013
P2, N=158, Recruiting, Sponsor: University of Miami
- Trial withdrawal: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - May 2, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Trial initiation date: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - May 2, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn Initiation date: Oct 2012 --> Jul 2013
- Enrollment change: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - May 2, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2012 --> Jul 2013 N=300 --> 0
- | Rituxan (rituximab) / Roche
Enrollment open: Rituximab in Systemic Sclerosis (clinicaltrials.gov) - May 2, 2013
P2/3, N=90, Recruiting, Sponsor: Assistance Publique - H
N=300 --> 0 Not yet recruiting --> Recruiting
- Enrollment closed: Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS (clinicaltrials.gov) - May 2, 2013
P1, N=24, Active, not recruiting, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Whole Body Vibration Therapy in Participants With MS Related Balance Deficits (clinicaltrials.gov) - May 1, 2013
P=N/A, N=80, Completed, Sponsor: Logan College of Chiropractic
Recruiting --> Active, not recruiting Recruiting --> Completed
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P2 trial: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - May 1, 2013
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed: Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Apr 30, 2013
P1/2, N=180, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: Multiple Sclerosis and Progressive Resistance Training (clinicaltrials.gov) - Apr 28, 2013
P=N/A, N=80, Active, not recruiting, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- New P4 trial: Efficacy of Fish Oil in Multiple Sclerosis (clinicaltrials.gov) - Apr 25, 2013
P4, N=50, Completed, Sponsor: Coordinación de Investigación en Salud, Mexico
- Trial completion: Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells (clinicaltrials.gov) - Apr 23, 2013
P=N/A, N=24, Completed, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- |||||||||| dimethyl fumarate / Generic mfg.
New P3 trial: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Apr 22, 2013
P3, N=202, Recruiting, Sponsor: Biogen Idec
- |||||| dimethyl fumarate / Generic mfg.
Enrollment open: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Apr 19, 2013
P3, N=202, Recruiting, Sponsor: Biogen Idec
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- ||| dalfampridine / Generic mfg.
Enrollment closed: Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (clinicaltrials.gov) - Apr 19, 2013
P2, N=132, Active, not recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg.
Enrollment closed: Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) (clinicaltrials.gov) - Apr 19, 2013
P2, N=142, Active, not recruiting, Sponsor: Philip Clements
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial termination: Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis (clinicaltrials.gov) - Apr 18, 2013
P4, N=1, Terminated, Sponsor: Elliot Frohman
Recruiting --> Active, not recruiting Recruiting --> Terminated; Poor Enrollment- schedule of assessments too complex and time-consuming.
- Trial completion: Improving New Learning and Memory in Multiple Sclerosis (clinicaltrials.gov) - Apr 18, 2013
P=N/A, N=88, Completed, Sponsor: Kessler Foundation
Recruiting --> Terminated; Poor Enrollment- schedule of assessments too complex and time-consuming. Active, not recruiting --> Completed
- New P1 trial: FARMS-1: Project FARMS: Fall Risk Reduction in Multiple Sclerosis (clinicaltrials.gov) - Apr 18, 2013
P1, N=33, Completed, Sponsor: University of Illinois at Urbana-Champaign
- Rebif (human IFN-β-1a) / EMD Serono
Trial withdrawal: Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects (clinicaltrials.gov) - Apr 17, 2013
P4, N=0, Withdrawn, Sponsor: EMD Serono
Active, not recruiting --> Completed Terminated --> Withdrawn
- ||||| arbaclofen placarbil (XP 19986) / Arbor Pharma, Indivior
Enrollment change: Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Apr 17, 2013
P3, N=218, Active, not recruiting, Sponsor: XenoPort, Inc.
Terminated --> Withdrawn N=275 --> 218
- ||||| arbaclofen placarbil (XP 19986) / Arbor Pharma, Indivior
Enrollment closed: Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Apr 17, 2013
P3, N=218, Active, not recruiting, Sponsor: XenoPort, Inc.
N=275 --> 218 Recruiting --> Active, not recruiting
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Trial initiation date: Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 17, 2013
P2, N=232, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Initiation date: Jul 2010 --> Nov 2011
- Trial withdrawal: Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA) (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=0, Withdrawn, Sponsor: Northwestern University
Initiation date: Jul 2010 --> Nov 2011 Recruiting --> Withdrawn
- Enrollment change: Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA) (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=0, Withdrawn, Sponsor: Northwestern University
Recruiting --> Withdrawn N=32 --> 0
- Synera (lidocaine 70 mg/tetracaine 70 mg/heated Topical Patch) / Miravo, Eurocept, Galen, Samaritan Pharma
Enrollment open: OUCH: Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (clinicaltrials.gov) - Apr 15, 2013
P4, N=30, Recruiting, Sponsor: Brown, Theodore R., M.D., MPH
N=32 --> 0 Not yet recruiting --> Recruiting
- Enrollment open: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). (clinicaltrials.gov) - Apr 14, 2013
P1, N=30, Recruiting, Sponsor: GE Healthcare
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ELND 002 / Perrigo Company
Trial termination: A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2013
P1, N=32, Terminated, Sponsor: Elan Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated
- ELND 002 / Perrigo Company
Enrollment change: A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2013
P1, N=32, Terminated, Sponsor: Elan Pharmaceuticals
Active, not recruiting --> Terminated N=100 --> 32
- ELND 002 / Perrigo Company
Trial termination: A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2013
P1, N=12, Terminated, Sponsor: Elan Pharmaceuticals
N=100 --> 32 Active, not recruiting --> Terminated
- ELND 002 / Perrigo Company
Enrollment change: A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2013
P1, N=12, Terminated, Sponsor: Elan Pharmaceuticals
Active, not recruiting --> Terminated N=80 --> 12
- Clinical: FFF: Pilot Study of Free From Falls Program in Multiple Sclerosis (clinicaltrials.gov) - Apr 9, 2013
P=N/A, N=36, Recruiting, Sponsor: Oregon Health and Science University
- Trial completion: Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women (clinicaltrials.gov) - Apr 9, 2013
P=N/A, N=35, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
N=80 --> 12 Recruiting --> Completed
- Trial completion: Effects of Vaporized Marijuana on Neuropathic Pain (clinicaltrials.gov) - Apr 4, 2013
P1/2, N=44, Completed, Sponsor: University of California, Davis
Recruiting --> Completed Active, not recruiting --> Completed
- New P2/3 trial: The Effect of GCSF in the Treatment of ALS Patients (clinicaltrials.gov) - Apr 3, 2013
P2/3, N=40, Completed, Sponsor: Tehran University of Medical Sciences
- ||| rHIgM22 / Acorda
Enrollment open: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - Apr 2, 2013
P1, N=71, Recruiting, Sponsor: Acorda Therapeutics
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- glatiramer acetate / Generic mfg.
Enrollment change: Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities (clinicaltrials.gov) - Apr 1, 2013
P4, N=10, Completed, Sponsor: University of Southern California
Not yet recruiting --> Recruiting N=18 --> 10
- Synera (lidocaine 70 mg/tetracaine 70 mg/heated Topical Patch) / Miravo, Eurocept, Galen, Samaritan Pharma
New P4 trial: OUCH: Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (clinicaltrials.gov) - Apr 1, 2013
P4, N=30, Recruiting, Sponsor: Brown, Theodore R., M.D., MPH
- dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Enrollment open: Clinical Trial Nuedexta in Subjects With ALS (clinicaltrials.gov) - Apr 1, 2013
P2, N=60, Recruiting, Sponsor: Center for Neurologic Study, La Jolla, California,
N=18 --> 10 Not yet recruiting --> Recruiting
- glatiramer acetate / Generic mfg.
Trial completion: Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities (clinicaltrials.gov) - Apr 1, 2013
P4, N=10, Completed, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Recruiting --> Completed